Home About Us Events Antibody Engineering & Therapeutics

Antibody Engineering & Therapeutics

December 12-16, 2021

San Diego, CA/ Hybrid


FUJIFILM Diosynth Biotechnologies is delighted to be exhibiting in person at Antibody Engineering & Therapeutics, December 12-16, 2021, San Diego, CA. Stop by our booth # 308. Meet our Commercial Team to learn more about our capabilities and how we could help you advance and deliver tomorrow’s medicines.

Join Us on Wednesday, December 15, 2021 at 12pm PDT
Pacific Ballroom 16

Fay Saunders, Head of Mammalian Cell Culture R&D, FUJIFILM Diosynth Biotechnologies, United Kingdom will be presenting on Cell Line Development using Apollo™X: A platform for accelerated Gene to GMP Timelines

  • Apollo™X is a cell line development platform, incorporating next generation screening technology, enhanced media selection and technical expertise. We will show that cell line development timeline reductions have been achieved through the introduction of a novel single cell cloning method which generates high producing clonal cell lines with both high probability and assurance of monoclonality. This talk will also describe how we can perform a ‘manufacturability assessment’ on multiple candidates which can assist in lead candidate decision making and gives confidence that the candidate selected can be developed into a commercially viable product. We will also share data demonstrating Apollo™X capabilities in expressing Bispecific Antibodies.


Visit our poster in person or virtual:

Development of a Bioinformatics Application to Facilitate Manufacturability Assessments for Monoclonal Antibodies by Arghya Barman and Graham McCreath, Data Science, FUJIFILM Diosynth Biotechnologies, Billingham, UK

  • Bioinformatics can add value to the development of protein based biologics by being able to predict features and properties which may influence options available during the development of the process, shortening process development timelines and facilitating the creation of a more robust manufacturing process. To achieve this goal, an innovative in-house software application ORBIT (Optimized Resource for Biologics Information and Toolkits) has been developed which can provide insight into the manufacturability of a biologic. When applied to monoclonal antibodies (mAbs), this includes being able to predict the experimental isoelectric point (pI) and critical quality attributes (CQA’s) such as aggregation hotspots, host cell protein association and charge heterogeneity. The application provides enhanced predictability of the quality attributes, and its versatility can be increased by hosting additional algorithms and advanced analytics.


For the agenda and registration click here